SLS - SELLAS Life Sciences Price-to-Projected Revenue Ratio
SELLAS Life Sciences develops advanced immunotherapeutic vaccines to combat the recurrence of dangerous tumors. The forward P/S trend confirms these developments, with the 41.00 metric reflecting current dynamics. A critical liquidity shortage and the potential failure of leukemia tests create a delisting threat. Geopolitical barriers and raw material logistics vulnerabilities remain constraining factors.
Comprehensive metric breakdowns and analytics for sellaslifesciences.com (SLS)
- market price and analyst price targets:
- market capitalization statistics:
- book value of equity indicators:
- business debt structure and liquidity details:
Total Debt to Equity Ratio SELLAS Life Sciences|SLS - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity SELLAS Life Sciences Group|SLS - Company Debts|Debts to Book Capitalization SELLAS Life Sciences|SLS - Long-Term Debt Volume|Company Short-Term Debts SELLAS Life Sciences|Quick Ratio sellaslifesciences.com
- financial results and valuation multiples details:
SLS - Company Net Income|Future Profit SELLAS Life Sciences|SLS - Company Value to Net Income|Future Price to Earnings SELLAS Life Sciences Group|SLS - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple SELLAS Life Sciences|SLS - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) SELLAS Life Sciences|SLS - Net earnings per share for the last four quarters|Quarterly EPS earnings growth sellaslifesciences.com|SLS - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year SELLAS Life Sciences
- total revenue and sales volume data:
Summary company analytics:SELLAS Life Sciences Group Inc. SLS
Fundamental screening of the asset begins with an analysis of the market capitalization to expected revenue ratio, which allows for an assessment of the business value relative to future cash flows. By analyzing the forward P/S trend, an investor identifies deviations of the current price from historical averages, which is critical for SELLAS Life Sciences (SLS), whose commercial drug implementation is temporarily limited by the pending FDA approval.
Analysis of competing companies
Price-to-Projected Revenue Ratio BeiGene ONC|Halozyme Therapeutics, Inc. - Price-to-Projected Revenue Ratio|RVMD - Price-to-Projected Revenue Ratio|AAPG: Price-to-Projected Revenue Ratio|CGON: Forward P/S Multiple|urogen.com (URGN) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Bicara Therapeutics|Personalis Inc (PSNL) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple ERAS (Erasca Corp)|DCTH (Delcath Corp) - Forward Price to Sales|Price-to-Projected Revenue Ratio Y-mAbs Therapeutics YMAB|aurabiosciences.com - Price-to-Projected Revenue Ratio|Candel - Forward P/S Multiple|Market Cap to Expected Sales Ratio Accuray Inc ARAY|ACTU: Forward P/S Multiple|Future Price to Revenue CTOR (Citius Oncology Inc)|HURA (TuHURA Biosciences Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio protaratx.com TARA|Forward Price-to-Revenue Multiple FATE (Fate Therapeutics)|WHWK (aadibio.com) - Forward Price to Sales|Price-to-Projected Revenue Ratio TScan Therapeutics, Inc. TCRX|Market Cap to Expected Sales Ratio Champions Oncology Inc (CSBR)|XBiotech USA - Forward P/S Multiple|CEL-SCI Corporation (CVM) - Forward Price-to-Revenue Multiple|OSTX: Forward P/S Multiple|RADX - Market Cap to Expected Sales Ratio|ARTV (Artiva Biotherapeutics Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Adlai Nortye Limited ANL|Price-to-Projected Revenue Ratio Veru Inc. (VERU)|tempesttx.com - Market Cap to Projected Revenue|Forward P/S Multiple XLO (Xilio Therapeutics)|RENB - Forward Price-to-Revenue Multiple|Mural Bio - Forward P/S Multiple|Market Cap to Future Revenue Ratio Kairos Pharma Ltd|onkuretherapeutics.com (OKUR) - Price-to-Projected Revenue Ratio|GDTC - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Curis Inc.|Apollomics Corp (APLM) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Tharimmune Corp (THAR)|Price-to-Projected Revenue Ratio ADVB (advanbiomed.com)|Price-to-Projected Revenue Ratio Genprex, Inc. GNPX|Market Cap to Expected Sales Ratio Calidi Biotherapeutics Inc. (CLDI)|Sunshine Biopharma, Inc. - Forward P/S Multiple|Xenetic Biosciences (XBIO) - Forward Price-to-Revenue Multiple|SLRX: Forward P/S Multiple|Kitov Pharma (PPBT) - Forward P/S Multiple|Price-to-Projected Revenue Ratio American Oncology Network Inc|Market Cap to Projected Revenue BGNE (beigene.com)|Forward P/S Multiple CKPT|Forward Price-to-Revenue Multiple elevationoncology.com ELEV|Forward P/S Multiple ICAD (iCAD)|Ikena Oncology Inc. (IKNA) - Market Cap to Future Revenue Ratio|NTBL - Price-to-Projected Revenue Ratio|Forward Price to Sales VIRX (Viracta Therapeutics)|MOR (MorphoSys) - Forward Price-to-Revenue Multiple|NAYA Biosciences Inc - Forward Price to Sales|AAPGV (Ascentage Pharma Group Ltd) - Forward P/S Multiple
